{
    "clinical_study": {
        "@rank": "52187", 
        "brief_summary": {
            "textblock": "OBJECTIVES: I.  Evaluate the efficacy of L-baclofen in patients with refractory trigeminal\n      neuralgia.\n\n      II.  Evaluate the safety and tolerance of L-baclofen in these patients."
        }, 
        "brief_title": "Randomized Study of L-Baclofen in Patients With Refractory Trigeminal Neuralgia", 
        "condition": "Trigeminal Neuralgia", 
        "condition_browse": {
            "mesh_term": [
                "Neuralgia", 
                "Trigeminal Neuralgia"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled, parallel study.\n\n      Patients are randomized to receive either L-baclofen or placebo orally at increasing daily\n      doses for 1 week.  Patients then continue to receive the maximum dosage acceptable for a 1\n      week maintenance period.\n\n      Patients, thereafter, may enroll in a long term open label study with L-baclofen.\n\n      Patients are followed at 1, 3, 6, 9, and 12 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics-- Idiopathic trigeminal neuralgia - Paroxysmal attacks of facial\n        or frontal pain lasting a few seconds to less than 2 minutes - Pain has at least 4 of the\n        following characteristics: Distribution along one or more divisions of the trigeminal\n        nerve Sudden, intense, sharp, superficial, stabbing, or burning quality Pain intensity\n        severe Precipitation from trigger areas, or by certain daily activities such as eating,\n        talking, washing the face, or cleaning the teeth Between paroxysms entirely asymptomatic -\n        No neurological deficit - Attacks are stereotyped in the individual patient - Exclusion of\n        other causes of facial pain by history, physical examination and special investigations\n        when necessary Must be uncontrolled or refractory as defined by occurrence of at least 2\n        paroxysms of pain per day despite conventional treatment with maximally tolerated doses of\n        carbamazepine --Prior/Concurrent Therapy-- No concurrent medication for trigeminal\n        neuralgia other than carbamazepine, phenytoin, and neurontin Concurrent medication for\n        other conditions allowed Concurrent medication must be on stable dose(s) --Patient\n        Characteristics-- Hepatic: No significant hepatic disease Renal: No significant renal\n        disease Neurological: No evidence of progressing neurological disorder (e.g., intracranial\n        neoplasm, multiple sclerosis) Other: No history of drug abuse Not pregnant Effective\n        contraception required of all fertile patients"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "30", 
        "firstreceived_date": "October 18, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004431", 
            "org_study_id": "199/13391", 
            "secondary_id": [
                "UPSOM-950686-9608", 
                "UPSOM-FDR000914"
            ]
        }, 
        "intervention": {
            "intervention_name": "L-baclofen", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Baclofen"
        }, 
        "keyword": [
            "neurologic and psychiatric disorders", 
            "rare disease", 
            "trigeminal neuralgia"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "contact": {
                "last_name": "Michael J Soso", 
                "phone": "412-648-1239"
            }, 
            "facility": {
                "address": {
                    "city": "Pittsburgh", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "15261"
                }, 
                "name": "University of Pittsburgh School of Medicine"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "overall_official": {
            "affiliation": "University of Pittsburgh", 
            "last_name": "Michael J. Soso", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004431"
        }, 
        "source": "FDA Office of Orphan Products Development", 
        "sponsors": {
            "collaborator": {
                "agency": "University of Pittsburgh", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "FDA Office of Orphan Products Development", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "June 1998", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2000"
    }, 
    "geocoordinates": {
        "University of Pittsburgh School of Medicine": "40.441 -79.996"
    }
}